The earnings call reflected a strong overall performance with significant revenue growth and positive trial results. However, challenges such as the impact of Medicare reforms and generic competition were noted.

Company Guidance

During AstraZeneca's Q3 2025 investor call, the company reiterated its strong financial performance and positive outlook. Total revenue increased by 11% through the first nine months of 2025, with core EPS growing by 15%. The oncology franchise saw a remarkable 16% increase, while the Biopharmaceuticals and Rare Disease divisions grew by 8% and 6%, respectively. AstraZeneca achieved 31 regulatory approvals and announced positive outcomes from 16 Phase III trials. The company remains confident in its $80 billion revenue ambition by 2030, supported by a robust pipeline and strategic investments. Additionally, AstraZeneca highlighted progress in the U.S. market, including a landmark agreement with the U.S. government, aiming to account for 50% of total revenue by 2030. Despite external challenges, the company is on track for its 2026 margin target, demonstrating resilience and strategic focus in maintaining growth momentum.

Strong Revenue Growth

Total revenue grew by 11% in the first nine months of 2025, driven by continued demand for innovative medicines. Core EPS increased by 15%.

Robust Oncology Segment

The oncology franchise grew by 16%, reflecting strong demand across the globe, particularly in the U.S. and emerging markets.

Significant Regulatory Approvals

AstraZeneca achieved 31 regulatory approvals across key regions since February, highlighting the company's rapid pace in bringing new medicines to market.

Positive Phase III Trial Results

The company announced positive results from 16 Phase III trials, including DESTINY-Breast05, TROPION-Breast02, and Bax24.

Strong Cash Flow and Financial Health

Cash flow from operating activities increased by 37% to $12.2 billion. The net debt-to-EBITDA ratio stands at 1.2x.

AstraZeneca (GB:AZN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

GB:AZN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Feb 05, 2026	2025 (Q4)	1.63 / -	1.591	―	―	―
Nov 06, 2025	2025 (Q3)	1.81 / 1.81	1.583	14.42% (+0.23)	―	―
Jul 29, 2025	2025 (Q2)	1.64 / 1.65	1.507	9.60% (+0.14)	―	―
Apr 29, 2025	2025 (Q1)	1.71 / 1.89	1.568	20.87% (+0.33)	―	―
Feb 06, 2025	2024 (Q4)	1.58 / 1.59	1.103	44.14% (+0.49)	―	―
Nov 12, 2024	2024 (Q3)	1.55 / 1.58	1.317	20.23% (+0.27)	―	―
Jul 25, 2024	2024 (Q2)	1.50 / 1.51	1.636	-7.91% (-0.13)	―	―
Apr 25, 2024	2024 (Q1)	1.45 / 1.57	1.461	7.29% (+0.11)	―	―
Feb 08, 2024	2023 (Q4)	1.11 / 1.10	1.05	5.07% (+0.05)	―	―
Nov 09, 2023	2023 (Q3)	1.28 / 1.32	1.271	3.59% (+0.05)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

GB:AZN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 06, 2025	12450.00p	12834.00p	+3.08%
Jul 29, 2025	10715.13p	11080.58p	+3.41%
Apr 29, 2025	10452.96p	10544.32p	+0.87%
Feb 06, 2025	10890.21p	11536.22p	+5.93%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does AstraZeneca PLC (GB:AZN) report earnings?

AstraZeneca PLC (GB:AZN) is schdueled to report earning on Feb 05, 2026, Before Open (Confirmed).

What is AstraZeneca PLC (GB:AZN) earnings time?

AstraZeneca PLC (GB:AZN) earnings time is at Feb 05, 2026, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of AstraZeneca PLC stock?

The P/E ratio of AstraZeneca is N/A.

What is GB:AZN EPS forecast?

GB:AZN EPS forecast for the fiscal quarter 2025 (Q4) is 1.63.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing